Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) (PA-24-187)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed) (PA-24-188)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required) (PA-24-189)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Notice of Special Interest (NOSI): Administrative Supplements to Promote Diversity for NINDS ADRD Awardees (NOT-NS-24-071)

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Due Date: Notice expires February 15, 2027.

NINDS Program Project Grant (P01 Clinical Trial Optional) (PAR-24-169)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional) (RFA-NS-24-016)

Sponsor: National Institutes of Health

Award: Applicants must not exceed $500,000 in direct costs per year for the UG3 phase and should rarely exceed $1,500,000 direct costs per year for the UH3 phase.

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional) (RFA-NS-24-017)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18 - Clinical Trial Not Allowed) (RFA-NS-24-031)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed) (PAR-24-144)

Sponsor: National Institutes of Health

Award: Applications may request up to $100,000 direct costs/year, excluding consortium facilities and administrative (F&A) costs. The scope of the proposed project should determine the project period. The maximum period of support is 4 years.

Due Date: Multiple due dates; see announcement.

Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed) (PAR-24-145)

Sponsor: National Institutes of Health

Award: Applications may request up to $125,000 direct costs/year, excluding consortium facilities and administrative (F&A) costs. The maximum period of support is 4 years.

Due Date: Multiple due dates; see announcement.

Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed) (PAR-24-121)

Sponsor: National Institute on Aging

Award: NIA intends to fund an estimate of 3-5 awards, corresponding to a total of $2.7 million, each year for fiscal years 2025, 2026, and 2027. Application budgets are not limited, but need to reflect the actual needs of the proposed project.

Due Date: Multiple due dates; see announcement.

NINDS Advanced Institutional Research Training Program (T32 Clinical Trial Not Allowed) (PAR-24-126)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) (RFA-MD-24-006)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) (PA-24-141)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Notice of Special Interest: Use of Digital Technology and Mobile Health to Improve Diagnosis, Assessments, Interventions, Management and Outcomes for Individuals with Down Syndrome (NOT-OD-24-044)

Sponsor: National Institutes of Health

Due Date: This notice applies to due dates through February 14, 2025.